唑来膦酸联合多西他赛治疗雄激素非依赖性前列腺癌

doi:10.3969/j.issn.1006-5725.2019.16.026

实用医学杂志 ›› 2019, Vol. 35 ›› Issue (16): 2633-2636.doi: 10.3969/j.issn.1006-5725.2019.16.026

唑来膦酸联合多西他赛治疗雄激素非依赖性前列腺癌

赵宏毅^1,2, 王亮¹

1西南医科大学附属医院泌尿外科（四川泸州 646000）;
2四川成都金堂县第一人民医院泌尿外科（成都 610400）

收稿日期:2019-01-22 出版日期:2019-08-27 发布日期:2019-08-27
通讯作者: 王亮 E-mail： wangliangcd@sina.com

Evaluation of zoledronic acid combined with docetaxel in the treatment of hormone-independent prostate cancer based on PSA

ZHAO Hongyi^*, WANG Liang

*Department of Urology, Affiliated Hospital of Southwest Medical University, Luzhou 646000, China

Received:2019-01-22 Online:2019-08-27 Published:2019-08-27
Contact: WANG Liang E-mail： wangliangcd@sina.com

摘要/Abstract

摘要： 目的研究唑来磷酸联合多西他赛治疗雄激素非依赖性前列腺癌（androgen independent prostate cancer, AIPC）的临床分析。方法选取2015年8月至2018年8月在我院治疗激素非依赖性前列腺癌患者132例,根据数字表法分为对照组和观察组,每组66例;对照组采用多西他赛治疗,观察组采用多西他赛联合唑来膦酸方案治疗。比较两组患者治疗前后前列腺癌特异抗原（prostate specific antigen,PSA）、疼痛评分、红细胞计数（RBC）、白细胞计数（WBC）、血小板计数（PLT）、恶心呕吐、静脉炎、谷丙转氨酶（ALT）、少尿无尿血尿毒副作用。结果观察组与对照组治疗前PSA指标差异无统计学意义（t = 0.241, P > 0.05）;治疗后对照组PSA指标明显高于观察组,差异具有统计学意义（t = 2.841,P < 0.05）。对照组与观察组治疗前疼痛评分差异无统计学意义（t = 0.275,P > 0.05）;观察组治疗后疼痛评分明显优于对照组,差异具有统计学意义（t = 3.245, P < 0.05）;观察组治疗后WBC、RBC、PLT及无尿或尿血毒副作用明显优于对照组,差异具有统计学意义（P < 0.05）;两组治疗后在恶心呕吐、静脉炎及ALT等指标比较差异无统计学意义（P > 0.05）。结论唑来膦酸联合多西他赛对于AIPC的治疗效果优于单独使用多西他赛,且两种药物联合使用还可降低治疗后的毒副作用的发生率,值得临床推广使用。

关键词: 唑来磷酸, 多西他赛, 激素非依赖性前列腺癌

Abstract: Objective To study the clinical analysis of zoledronic acid combined with docetaxel in the treatment of hormone-independent prostate cancer. Methods 132 patients with hormone-independent prostate cancer treated in our hospital from August 2015 to August 2018 were divided into control group and experimental group according to the digital table method, 66 cases in each group. The control group was treated with docetaxel, while the experimental group was treated with docetaxel combined with zoledronic acid. The side effects of prostate cancer specific antigen （PSA）, pain score, RBC, WBC, platelet, nausea and vomiting, phlebitis, ALT and oliguria without hematuria were compared between the two groups before and after treatment. Results There was no significant difference in the PSA indexes between the experimental group and the control group before treatment （t = 0.241, P > 0.05）. After treatment, the PSA indexes in the control group were significantly higher than those in the experimental group （t = 2.841, P < 0.05）. There was no significant difference in pain score between the control group and the experimental group before treatment （t = 0.275, P > 0.05）. The pain score in the experimental group was significantly better than that in the control group after treatment （t = 3.245, P < 0.05）. The toxic side effects of WBC, RBC, platelet and anuria or urinary blood in the experimental group after treatment were significantly better than those in the control group with statistical significance （P < 0.05）. There was no significant difference in nausea, vomiting, phlebitis and ALT （P > 0.05）. Multivariate COX analysis showed that the lowest values of PSA, HB and PSA were the main risk factors for advanced metastatic AIPC. Conclusion Zoledronic acid combined with docetaxel is superior to docetaxel alone in the treatment of hormone-independent prostate cancer, and the combination of the two drugs can also reduce the incidence of toxic and side effects after treatment, which is worthy of clinical application.

Key words: zoledronic acid, docetaxel, hormone independent prostate cancer

赵宏毅, 王亮. 唑来膦酸联合多西他赛治疗雄激素非依赖性前列腺癌[J]. 实用医学杂志, 2019, 35(16): 2633-2636.

ZHAO Hongyi, WANG Liang. Evaluation of zoledronic acid combined with docetaxel in the treatment of hormone-independent prostate cancer based on PSA[J]. The Journal of Practical Medicine, 2019, 35(16): 2633-2636.

参考文献 14

[1]	王公臣, 徐海岩, 张铁辉. 雄激素非依赖性前列腺癌发生机制的研究进展[J]. 医学综述, 2016, 22(14):2791-2795.
[2]	SIEGEL R L,MILLERKD,JEMAL A.Cancer statistics,2016[J]. Cancer J Clin, 2016,66(5):7-30.
[3]	楼雨蛟, 张青川. 人参皂苷抑制去势抵抗性前列腺癌的分子生物学机制[J]. 现代肿瘤医学, 2018, 245(11):156-160.
[4]	HONDA S, KIRINO Y.SHOT-RNAs: A novel class of tRNA-derived functional RNAs expressed in hormone-dependent cancers[J]. Mol Cell Oncol, 2016, 3(2):e1079672.
[5]	SWEENEY C J, CHEN Y H, CARDUCCI M, et al.Chemohormonal therapy in metastatic hormone-sensitive prostate cancer[J]. N Engl J Med, 2015, 373(8):737.
[6]	曹玉霖, 李飞, 赵欢,等. 染料木黄酮通过PI3K/AKT途径抑制雄激素非依赖性LNCaP细胞[J]. 安徽医科大学学报, 2018, 53(7):1017-1021.
[7]	OLMOS D, BREWER D, CLARK J et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: A prospective, two-stage study[J]. Lancet Oncol, 2012, 13(11):1114-1124.
[8]	CHENG J, YANG K, ZHANG Q, et al.The role of mesenchymal stem cells in promoting the transformation of androgen-dependent human prostate cancer cells into androgen-independent manner[J]. Sci Rep, 2016, 6(1):16993.
[9]	蒋鸿涛, 吴涛, 章运生,等. 盐霉素及mTOR信号通路对前列腺癌DU145干细胞的影响[J]. 实用医学杂志, 2017, 33(13):28-32.
[10]	MORETTI R M, MONTAGNANI MARELLI M, MOTTA M, et al.Activation of the orphan nuclear receptor RORαinduces growth arrest in androgen-independent DU 145 prostate cancer cells[J]. Prostate, 2015, 46(4):327-335.
[11]	YUMIN W, TINGTING Q, WANGQIANG H, et al.Genome-wide methylation patterns in androgen-independent prostate cancer cells: A comprehensive analysis combining MeDIP-Bisulfite, RNA, and microRNA sequencing data[J]. Genes, 2018, 9(1):32-35.
[12]	张峰, 焦举, 谢良骏. 99mTc-MDP SPECT／CT全身骨显像诊断前列腺癌骨转移的临床价值[J]. 实用医学杂志, 2017, 33(11):1774-1777.
[13]	FRANCINI E, SWEENEY C J.Docetaxel activity in the era of life-prolonging hormonal therapies for metastatic castration-resistant prostate cancer[J]. Eur Urol, 2016, 70(3):410-412.
[14]	BILEN M, HESS K, SUBUDHI S, et al.Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy[J]. Cancer Chemoth Pharmacol, 2017, 80(11):1-7.

唑来膦酸联合多西他赛治疗雄激素非依赖性前列腺癌

Evaluation of zoledronic acid combined with docetaxel in the treatment of hormone-independent prostate cancer based on PSA

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 14

相关文章 0

编辑推荐

Metrics

本文评价